NanoViricides (NNVC) vs Serina Therapeutics (SER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NanoViricides (NNVC) has outperformed Serina Therapeutics (SER) over the past year, losing 10.2% versus a loss of 71.9%. Over five years, NNVC leads with a -76.5% price change compared with -95.6% for SER. Serina Therapeutics is the larger company by market cap ($29.8 million vs $29.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NNVC | SER |
|---|---|---|
| Share price | $1.14 | $1.12 |
| Market cap | $29.13M | $29.76M |
| 1-day change | -2.56% | -6.67% |
| YTD return | +0.88% | -41.45% |
| 1-year return | -10.24% | -71.93% |
| 5-year return | -76.54% | -95.64% |
| EPS (TTM) | $-0.53 | $-1.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $130.00K |
| Revenue growth (YoY) | — | +132.14% |
| Net income (latest FY) | $-8.22M | $-19.18M |
| Operating margin | — | -18478.46% |
| Net margin | — | -14755.38% |
| 52-week high | $1.93 | $4.26 |
| 52-week low | $0.85 | $1.06 |
| Distance from 52-week high | -40.93% | -73.71% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +426.32% | +748.21% |
| Average volume | 356.86K | 68.98K |
| Shares outstanding | 25.55M | 26.57M |
| Employees | 7 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NNVC has outperformed SER by 61.7 percentage points over the past year.
About NanoViricides
NNVC stock →NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection; The latter, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Serina Therapeutics
SER stock →Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
NNVC vs SER FAQ
Which is bigger, NanoViricides or Serina Therapeutics?
Serina Therapeutics (SER) is larger, with a market capitalization of $29.76M compared with $29.13M for NanoViricides (NNVC).
Which stock has performed better over the past year, NNVC or SER?
NNVC returned -10.24% over the past 12 months, compared with -71.93% for SER (price return, excluding dividends). Past performance does not predict future results.
Are NanoViricides and Serina Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.